Forex
World
Market
Business
Cryptocurrency
Commodities
MAP
Publish for free
Business
financetom
/
Business
/
--Eli Lilly Wins FDA Approval for Alzheimer's Drug Kisunla
News
World
Market
Environment
Technology
Personal Finance
Politics
Retail
Business
Economy
Cryptocurrency
Forex
Stocks Market
Commodities
--Eli Lilly Wins FDA Approval for Alzheimer's Drug Kisunla
Jul 2, 2024 11:06 AM
01:40 PM EDT, 07/02/2024 (MT Newswires) --
Price: 902.50, Change: -11.87, Percent Change: -1.30
Previous page:
Bausch Health Q2 Adjusted Profit Declines, Revenue up 11%; Revenue Guidance Raised
Next page:
US progressives push for Nvidia antitrust investigation
Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Release time ⇩
Release time ⇧
Like count ⇩
Show More Comments
Related Articles >
Bausch Health Q2 Adjusted Profit Declines, Revenue up 11%; Revenue Guidance Raised
Aug 1, 2024
07:55 AM EDT, 08/01/2024 (MT Newswires) -- Bausch Health ( BHC ) on Thursday said adjusted profit and revenue rose in the second quarter. Adjusted profit of US$328 million compares with US$300 million last year. Bausch Health ( BHC ) reported total revenue increased 11% to US$2.4 billion. The company raised its full year revenue guidance to US$9.65 billion from...
US progressives push for Nvidia antitrust investigation
Aug 1, 2024
Aug 1 (Reuters) - U.S. progressive groups and Democratic Senator Elizabeth Warren pressed the Department of Justice to investigate Nvidia ( NVDA ) over competition concerns, citing the company's dominance of the market for the chips driving the artificial-intelligence boom. Demand Progress and nine other groups wrote a letter this week urging Department of Justice antitrust chief Jonathan Kanter to...
Aptiv's Q2 Adjusted Earnings Rise, Revenue Falls; Raises 2024 Earnings Guidance; Shares Gain
Aug 1, 2024
08:03 AM EDT, 08/01/2024 (MT Newswires) -- Aptiv ( APTV ) reported Q2 adjusted earnings of $1.58 per diluted share on Thursday, up from $1.25 a year earlier. Analysts polled by Capital IQ expected $1.42. Revenue for the quarter ended June 30 was $5.05 billion compared with $5.20 billion a year earlier. Analysts surveyed by Capital IQ expected $5.30 billion....
Neurocrine Biosciences Q2 Adjusted Earnings, Revenue Climb -- Shares Up Pre-Bell
Aug 1, 2024
08:14 AM EDT, 08/01/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) reported Q2 adjusted earnings Thursday of $1.63 per diluted share, up from $1.25 a year earlier. Analysts polled by Capital IQ expected $1.53. Revenue for the quarter ended June 30 was $590.2 million, up from $452.7 million a year earlier. Analysts polled by Capital IQ expected $546.5 million....
About
Terms and Conditions
Privacy policy
Cookie Settings
Contact Us
Services
Login
register
financetom
Market
Personal Finance
Business
Economy
Cryptocurrency
MAP
Links
zpostcode
Recruit
weather
mreligion
Yellowpages
sport
constellation
shopping
name
game
directory
literature
Word
tour
furnish
Lottery
tftnews
lyrics
News
digital
car
dir
Edu
Finance
Copyright 2023-2026 -
www.financetom.com
All Rights Reserved
News
World
Market
Environment
Technology
Personal Finance
Politics
Retail
Business
Economy
Cryptocurrency
MAP